In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Vivani Medical, with a price target of $4.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Yi Chen has given his Buy rating due to a combination of factors that highlight Vivani Medical’s promising future prospects. The company has successfully extended its cash runway into the second half of 2026, thanks to recent share purchase agreements that have brought in significant funds. This financial stability allows Vivani to focus on advancing its innovative projects, such as the NPM-139 semaglutide implant, which has shown promising results in preclinical studies by maintaining substantial weight loss over an extended period.
Moreover, the potential for NPM-139 to improve the safety and tolerability of existing semaglutide therapies positions it as a strong candidate for clinical development. Vivani’s strategic plans also include the spin-off of Cortigent, Inc., which is expected to become a publicly traded company, further enhancing the company’s growth potential. These factors collectively support Yi Chen’s confidence in Vivani Medical’s stock, justifying the Buy rating and a price target of $4.
According to TipRanks, Chen is an analyst with an average return of -7.6% and a 37.93% success rate. Chen covers the Healthcare sector, focusing on stocks such as Anixa Biosciences, Lipocine, and RegenXBio.